Intelligence · Patents
Patents expiring in 2043
Annual patent cliff calendar for 2043 — US pharmaceutical patents by expiration date.
- Patents
- 1,718
Quick answer
1,718 indexed pharmaceutical patents have expiration dates in 2043. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11806334
Non-sedating dexmedetomidine treatment regimens
granted -
US 11807636
IRAK degraders and uses thereof
granted -
US 11806406
Virus-like particle conjugates for diagnosis and treatment of tumors
granted -
US 11806504
Device, system and methods for the oral delivery of therapeutic compounds
granted -
US 11806336
Methods and compositions for treatment of epileptic disorders
granted -
US 11806398
Citrate buffered VEGF antagonist formulations
granted -
US 11806432
Compositions, methods and uses for thermally stable multi-targeted antigens
granted -
US 11807646
4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19)
granted -
US 11813282
Injectable scaffold for treatment of intracranial aneurysms and related technology
granted -
US 11813257
Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors
granted -
US 11814376
Hepatitis b core protein modulators
granted -
US 11813319
Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L
granted -
US 11813357
Treatment of hip pain with sustained-release liposomal anesthetic compositions
granted -
US 11813335
Pyrrolobenzodiazepine-antibody conjugates
granted -
US 11814432
Anti-HLA-A2 antibodies, related chimeric antigen receptors, and uses thereof
granted -
US 11814624
Targeted non-viral DNA insertions
granted -
US 11813267
DNA-PK inhibitors
granted -
US 11813277
Methods and agents for modulating inflammation
granted -
US 11813278
Highly active compounds against COVID-19
granted -
US 11813241
Multi-arm polymeric prodrug conjugates of taxane-based compounds
granted -
US 11813123
Ultrasound responsive micro-composite markers
granted -
US 11813341
Dental product with enhanced toughness
granted -
US 11813235
Guanfacine as an anti-virulence agent
granted -
US 11813310
Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia
granted -
US 11813358
Lipid nanodisc formation by polymers having a pendant hydrophobic group
granted -
US 11814377
Pyrimidine compound as JAK kinase inhibitor
granted -
US 11814439
Anti-CD20 antibody compositions
granted -
US 11814657
Modified DNase and uses thereof
granted -
US 11813314
Method of delivering a somatostatin compound into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 11813320
Genetically engineered foot and mouth disease virus and related proteins, polynucleotides, compositions, methods and systems
granted -
US 11813377
Microfiber structures and methods of synthesis and use thereof
granted -
US 11813485
Systems and methods for histotripsy immunosensitization
granted -
US 11814371
Heterocyclic compound
granted -
US 11814373
Methods and compounds for restoring mutant p53 function
granted -
US 11813359
Sustained release olanzapine formulations
granted -
US 11814394
Exatecan derivatives, linker-payloads, and conjugates and thereof
granted -
US 11814428
Anti-PTCRA antibody-drug conjugates and uses thereof
granted -
US 11814431
B7-H4 antibodies and methods of use thereof
granted -
US 11813316
Lentiviral vector for treating hemoglobin disorders
granted -
US 11814625
Aptamers as a therapeutic tool to prevent protein aggregation in neurodegenerative disease
granted -
US 11814659
Tunable nanoscale cages from self-assembling DNA and protein building blocks
granted -
US 11814427
Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
granted -
US 11814410
Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
granted -
US 11814622
OPA1 antisense oligomers for treatment of conditions and diseases
granted -
US 11814440
Glypican 2 as a cancer marker and therapeutic target
granted -
US 11814444
Cyclic polypeptides for PCSK9 inhibition
granted -
US 11814445
Cyclic polypeptides for PCSK9 inhibition
granted -
US 11814447
Peptide ligands for binding to EphA2
granted
Frequently asked questions
How many pharma patents expire in 2043?
1,718 published patents in our USPTO index have expiration dates falling in calendar year 2043.